Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
4 Articles
4 Articles
South Korean pharmaceutical giant Samsung Biologics sees no need to expand Polypeptides' factory in Limhamn after the billion-kroner bid. At the same time, the company is open to future investments if demand increases.
Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal - European Biotechnology Magazine
Consolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, Samsung Biologics aims to strengthen its position in the fast-growing market for complex biopharmaceuticals. The post Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal appeared first on European Biotechnology Magazine.
Samsung Biologics announced the initiation of a public cash tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG, a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based pharmaceuticals...
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
